Repare Therapeutics Inc. (RPTX)
NASDAQ: RPTX · Real-Time Price · USD
1.019
-0.031 (-2.92%)
Mar 31, 2025, 1:23 PM EDT - Market open
Repare Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Repare Therapeutics stock have an average target of 4.50, with a low estimate of 4.00 and a high estimate of 5.00. The average target predicts an increase of 341.48% from the current stock price of 1.02.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Repare Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $5 | Strong Buy | Maintains | $10 → $5 | +390.53% | Mar 7, 2025 |
| LifeSci Capital | LifeSci Capital | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Dec 13, 2024 |
| Stifel | Stifel | Strong Buy Maintains $9 → $4 | Strong Buy | Maintains | $9 → $4 | +292.43% | Dec 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +881.07% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +881.07% | Oct 24, 2024 |
Financial Forecast
Revenue This Year
7.99M
from 53.48M
Decreased by -85.06%
Revenue Next Year
8.56M
from 7.99M
Increased by 7.11%
EPS This Year
-1.82
from -2.00
EPS Next Year
-1.23
from -1.82
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 21.0M | 21.0M | 60.6M | ||
| Avg | 8.0M | 8.6M | 29.4M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -60.7% | 162.8% | 607.8% | ||
| Avg | -85.1% | 7.1% | 243.8% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.68 | -0.47 | -1.01 |
| Avg | -1.82 | -1.23 | -1.69 |
| Low | -2.38 | -1.71 | -2.30 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.